1044.7000 16.60 (1.61%)
NSE Oct 03, 2025 15:48 PM
Volume: 49,337
 

1044.70
1.61%
ICICI Securities Limited
Tatva Chintan’s Q4FY23 revenue rose 26.4% YoY to Rs1.2bn as SDA revenue recovered to Rs0.5bn, up 41% YoY. However, gross profit margin dip of 400bps to 39.8% was disappointing (partly from a change in product mix) considering the company has guided for a sequential improvement in margins.
Tatva Chintan Pharma Chem Ltd. is trading below its 30 day SMA of 1053.7
More from Tatva Chintan Pha…
All earning calls
Investor presentations from Tatva Chintan Pha…
All investor presentations